Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026 (NASDAQ:ARCT)

Arcturus (ARCT) Q4 2025 earnings call recap: ARCT-032 Phase II CF plans, ARCT-810 regulatory path, cash runway to 2028—read key takeaways.

You will be redirected in 10 seconds.